What We Know About Oxidative Stress in Patients with Chronic Kidney Disease on Dialysis-Clinical Effects, Potential Treatment, and Prevention

Seminars in Dialysis

Volumn 24, Issue 1, 2011, Pages 56-64

  Del Vecchio, Lucia ^a   Locatelli, Francesco ^a   Carini, Marina ^b  

^a A MANZONI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT;

ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

ANTIOXIDANTS; ATHEROSCLEROSIS; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 79951793820     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00819.x     Document Type: Article

References (96)

1. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731):2073-2081, 2010
2. Astor BC, Hallan SI, Miller ER III, Yeung E, Coresh J: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 167(10):1226-1234, 2008
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296-1305, 2004
4. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
5. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V: Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373(9668):1009-1015, 2009
6. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238-248, 2005
7. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160(1):1-40, 2006
8. Sies H: Oxidants and antioxidants. Exp Physiol 82:291-295, 1997
9. Elahi MM, Kong YX, Matata BM: Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev 2(5):259-269, 2009
10. Descamps-Latscha B, Drueke T, Witko-Sarsat V: Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 14(3):193-199, 2001
11. Kao MP, Ang DS, Pall A, Struthers AD: Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 24(1):1-8, 2010
12. Vásquez-Vivar J: Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic Biol Med 47(8):1108-1119, 2009
13. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, Malinski T, Lüscher TF: Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 101(7):1530-1537, 1998
14. Ozaki M, Kawashima S, Yamashita T, Hirase T, Ohashi Y, Inoue N, Hirata K, Yokoyama M: Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 66(9):851-856, 2002
15. Laakso J, Mervaala E, Himberg JJ, Teräväinen TL, Karppanen H, Vapaatalo H, Lapatto R: Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 32(5):902-906, 1998
16. Himmelfarb J: Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 22(6):636-643, 2009
17. Kemp M, Go YM, Jones DP: Nonequilibrium thermodynamics of thiol/disulfide redox systems: a perspective on redox systems biology. Free Radic Biol Med 44(6):921-937, 2008
18. Aldini G, Dalle-Donne I, Colombo R, Maffei Facino R, Milzani A, Carini M: Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. ChemMedChem 1(10):1045-1058, 2006
19. Aldini G, Dalle-Donne I, Maffei Facino R, Milzani A, Carini M: Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev 27(6):817-868, 2007
20. Anderson MM, Hazen SL, Hsu FF, Heinecke JW: Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A Mechanism for the generation of highly reactive a-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 9:424-432, 1997
21. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J: Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 19(3):593-599, 2008
22. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D: Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48(5):752-760, 2006
23. Moh A, Sakata N, Takebayashi S, Tateishi K, Nagai R, Horiuchi S, Chihara J: Increased production of urea hydrogen peroxide from Maillard reaction and a UHP-Fenton pathway related to glycoxidation damage in chronic renal failure. J Am Soc Nephrol 15(4):1077-2085, 2004
24. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B: Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 28(2):158-167, 1985
25. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E: The antioxidant properties of serum albumin. FEBS Lett 582(13):1783-1787, 2008
26. Soejima A, Matsuzawa N, Hayashi T, Kimura R, Ootsuka T, Fukuoka K, Yamada A, Nagasawa T, Era S: Alteration of redox state of human serum albumin before and after hemodialysis. Blood Purif 22(6):525-529, 2004
27. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65(3):1009-1016, 2004
28. Caimi G, Carollo C, Montana M, Iatrino R, Bondì B, Lo Presti R: Nitric oxide metabolites, leukocyte activation markers and oxidative status in dialyzed subjects. Blood Purif 27(2):194-198, 2009
29. Massy ZA, Borderie D, Nguyen-Khoa T, Drüeke TB, Ekindjian OG, Lacour B: Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant 18(1):153-157, 2003
30. Honda H, Ueda M, Kojima S, Mashiba S, Hirai Y, Hosaka N, Suzuki H, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T: Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol 4(1):142-151, 2009
31. Stoyanova E, Sandoval SB, Zúñiga LA, El-Yamani N, Coll E, Pastor S, Reyes J, Andrés E, Ballarin J, Xamena N, Marcos R: Oxidative DNA damage in chronic renal failure patients. Nephrol Dial Transplant 25(3):879-885, 2010
32. Granata S, Zaza G, Simone S, Villani G, Latorre D, Pontrelli P, Carella M, Schena FP, Grandaliano G, Pertosa G: Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 10:388, 2009
33. Miyata T, Saito A, Kurokawa K, van Ypersele de Strihou C: Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity. Nephrol Dial Transplant 16(Suppl 4):8-11, 2001
34. Pieniazek A, Brzeszczynska J, Kruszynska I, Gwozdzinski K: Investigation of albumin properties in patients with chronic renal failure. Free Radic Res 43(10):1008-1018, 2009
35. Miyata T, Sugiyama S, Saito A, Kurokawa K: Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int Suppl 78:S25-S31, 2001
36. Lin YS, Hung SC, Wei YH, Tarng DC: GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. J Am Soc Nephrol 20(2):405-415, 2009
37. Beal MF: Oxidatively modified proteins in aging and disease. Free Radic Biol Med 32:797-803, 2002
38. Levine RL: Carbonyl modified proteins in cellular regulations, aging, and disease. Free Radic Biol Med 32:790-796, 2002
39. Sohal RS: Role of oxidative stress protein oxidation in the aging process. Free Radic Biol Med 33:37-44, 2002
40. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A: Protein carbonylation in human diseases. Trends Mol Med 9:169-176, 2003
41. Halliwell B, Gutteridge JM: Free Radicals in Biology and Medicine, 3rd ed. Oxford, UK: Oxford Science Pubblications, 2001
42. Berliner J, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20:707-727, 1996
43. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 142:67-77, 1999
44. Malle E, Waeg G, Schreiber R, Gröne EF, Sattler W, Gröne HJ: Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 267(14):4495-4503, 2000
45. Tanaka M, Abe Y, Furukado S, Miwa K, Sakaguchi M, Sakoda S, Kitagawa K: Chronic kidney disease and carotid atherosclerosis. J Stroke Cerebrovasc Dis 2010 [Epub ahead of print]
46. Dursun B, Dursun E, Suleymanlar G, Ozben B, Capraz I, Apaydin A, Ozben T: The effect of hemodialysis on accelerated atherosclerosis in diabetic patients: correlation of carotid artery intima-media thickness with oxidative stress. J Diabetes Complications 23(4):257-264, 2009
47. Dursun B, Dursun E, Suleymanlar G, Ozben B, Capraz I, Apaydin A, Ozben T: Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant 23(5):1697-1703, 2008
48. Dursun B, Dursun E, Capraz I, Ozben T, Apaydin A, Suleymanlar G: Are uremia, diabetes, and atherosclerosis linked with impaired antioxidant mechanisms? J Investig Med 56(2):545-552, 2008
49. Whitsett J, Picklo MJ Sr, Vasquez-Vivar J: 4-Hydroxy-2-nonenal increases superooxide anion radical in endothelial cells via stimulated GTP cyclohydrolase proteasomal degradation. Arterioscler Thromb Vasc Biol 27:2340-2347, 2007
50. Pope AJ, Druhan L, Guzman JE, Forbes SP, Murugesan V, Lu D, Xia Y, Chicoine LG, Parinandi NL, Cardounel AJ: Role of DDAH-1 in lipid peroxidation product-mediated inhibition of endothelial NO generation. Am J Physiol Cell Physiol 293:C1679-C1686, 2007
51. Costa-Hong V, Bortolotto LA, Jorgetti V, Consolim-Colombo F, Krieger EM, Lima JJ: Oxidative stress and endothelial dysfunction in chronic kidney disease. Arq Bras Cardiol 92(5):381-386, 2009
52. Kocak H, Gumuslu S, Sahin E, Ceken K, Gocmen YA, Yakupoglu G, Ersoy FF, Tuncer M: Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology (Carlton) 14(3):273-280, 2009
53. Forbes SP, Druhan LJ, Guzman JE, Parinandi N, Zhang L, Green-Church KB, Cardounel AJ: Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in NO regulation. Biochemistry 47:1819-1826, 2008
54. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47(1):42-50, 2006
55. Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J: ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 19(2):388-395, 2008
56. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358(9299):2113-2117, 2001
57. Spinale FG: Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. Circ Res 91(12):1082-1084, 2002
58. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger R; CREED Investigators: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62(1):339-645; 2002
59. Shi B, Ni Z, Zhou W, Yu Z, Gu L, Mou S, Fang W, Wang Q, Cao L, Yan Y, Qian J: Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 21(5):444-448, 2010
60. Dalfino G, Simone S, Porreca S, Cosola C, Balestra C, Manno C, Schena FP, Grandaliano G, Pertosa G: Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis 211(2):418-423, 2010
61. Bayés B, Pastor MC, Bonal J, Juncà J, Hernandez JM, Riutort N, Foraster A, Romero R: Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 18(1):106-112, 2003
62. Stenvinkel P, Diczfalusy U, Lindholm B, Heimbürger O: Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant 19(4):972-976, 2004
63. Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F: Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 15(1):137-141, 2005
64. Shooley JC, Kullgren B, Allison AC: Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 67:11-17, 1987
65. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hypo responsiveness in maintenance haemodialysis patients. Am J Kidney Dis 42(4):761-773, 2003
66. Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med 47:204-211, 1999
67. Kato A, Odamaki M, Hishida A: Blood 8-hydroxy-2'-deoxyguanosine is associated with erythropoietin resistance in hemodialysis patients. Nephrol Dial Transplant 18:931-936, 2003
68. Siems W, Carluccio F, Grune T, Jakstadt M, Quast S, Hampl H, Sommerburg O: Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia. Clin Nephrol 58(Suppl 1):S20-S25, 2002
69. Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU: Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin Nephrol 52:239-245, 1999
70. Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H: Oxidation parameters in complete correction of renal anemia. Clin Nephrol 53(Suppl 1):S30-S35, 2000
71. Monostori P, Hracskó Z, Karg E, Varga IS, Kiss Z, Boros T, Kiss E, Haszon I, Papp F, Sümegi V, Bereczki C, Túri S: Erythropoiesis-stimulating agent withdrawal and oxidative stress in hemodialysis. Clin Nephrol 71(5):521-526, 2009
72. Ganguli A, Kohli HS, Khullar M, Lal Gupta K, Jha V, Sakhuja V: Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail 31(2):106-110, 2009
73. Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJ, Frigo TB, Lewis JM: Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 39(6):489-496, 2009
74. Mafra D, Santos FR, Lobo JC, de Mattos Grosso D, Barreira AL, Velarde LG, Abdalla DS, Leite M Jr: Alpha-tocopherol supplementation decreases electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis patients. Nephrol Dial Transplant 24(5):1587-1592, 2009
75. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356(9237):1213-1218, 2000
76. Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, Bosch J, Dagenais GR, Yusuf S; HOPE Investigators: Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 65(4):1375-1380, 2004
77. Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, Teerlink T, van Dorp W, Stehouwer CD: Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167(12):1262-1270, 2007
78. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canaud B: Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 12(11):2312-2317, 1997
79. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11(3):539-549, 2000
80. Morimoto H, Nakao K, Fukuoka K, Sarai A, Yano A, Kihara T, Fukuda S, Wada J, Makino H: Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant 20(12):2775-2782, 2005
81. Takouli L, Hadjiyannakos D, Metaxaki P, Sideris V, Filiopoulos V, Anogiati A, Vlassopoulos D: Vitamin E-coated cellulose acetate dialysis membrane: long-term effect on inflammation and oxidative stress. Ren Fail 32(3):287-293, 2010
82. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T: Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 101(9):1002-1006, 2000
83. Cruz DN, De Cal M, Garzotto F, Brendolan A, Nalesso D, Corradi V, Ronco C: Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. Int J Artif Organs 31(6):545-552, 2008
84. Andrulli S, Di Filippo S, Manzoni C, Stefanelli L, Floridi A, Galli F, Locatelli F: Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract 115(1):c82-c89, 2010
85. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, Descamps-Latscha B, Drüeke TB, Massy ZA: The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 67(6):2288-2294, 2005
86. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107(7):992-995, 2003
87. Thaha M, Widodo, Pranawa W, Yogiantoro M, Tomino Y: Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Clin Nephrol 69(1):24-32, 2008
88. Nascimento MM, Suliman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, Riella MC, Lindholm B, Anderstam B: Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int 30(3):336-342, 2010
89. Takahashi N, Morimoto S, Okigaki M, Seo M, Someya K, Morita T, Matsubara H, Sugiura T, Iwasaka T: Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients. Nephrol Dial Transplant 2010 [Epub ahead of print]
90. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G: Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 41(6):381-386, 2008
91. Fumeron C, Nguyen-Khoa T, Saltiel C, Kebede M, Buisson C, Drüeke TB, Lacour B, Massy ZA: Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 20:1874-1879, 2005
92. Chan D, Irish A, Croft KD, Dogra G: Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients. Nephrol Dial Transplant 21(1):234-235, 2006
93. Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, Hemmelgarn BR; Alberta Kidney Disease Network: Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 54(6):1089-1097, 2009
94. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov IG, Vanholder R, Lacour B, Drüeke TB, Massy ZA: Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112(18):2875-2882, 2005
95. Peres AT, Dalboni MA, Canziani ME, Manfredi SR, Carvalho JT, Batista MC, Cuppari L, Carvalho AB, Moyses RM, Guimarães N, Jorgetti V, Andreoli MC, Draibe SA, Cendoroglo M: Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodial Int 13(3):271-277, 2009
96. Calò LA, Naso A, Davis PA, Pagnin E, Corradini R, Tommasi A, Sereni L, Ragazzi E: Hemodiafiltration with online regeneration of ultrafiltrate: effect on heme-oxygenase-1 and inducible subunit of nitric oxide synthase and implication for oxidative stress and inflammation. Artif Organs 2010 [Epub ahead of print]